Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes
Stem Cell Reviews and Reports, Volume 10, No. 3, Year 2014
Notification
URL copied to clipboard!
Description
Diabetes mellitus is the most prevailing disease with progressive incidence worldwide. To date, the pathogenesis of diabetes is far to be understood, and there is no permanent treatment available for diabetes. One of the promising approaches to understand and cure diabetes is to use pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced PCSs (iPSCs). ESCs and iPSCs have a great potential to differentiate into all cell types, and they have a high ability to differentiate into insulin-secreting β cells. Obtaining PSCs genetically identical to the patient presenting with diabetes has been a longstanding dream for the in vitro modeling of disease and ultimately cell therapy. For several years, somatic cell nuclear transfer (SCNT) was the method of choice to generate patient-specific ESC lines. However, this technology faces ethical and practical concerns. Interestingly, the recently established iPSC technology overcomes the major problems of other stem cell types including the lack of ethical concern and no risk of immune rejection. Several iPSC lines have been recently generated from patients with different types of diabetes, and most of these cell lines are able to differentiate into insulin-secreting β cells. In this review, we summarize recent advances in the differentiation of pancreatic β cells from PSCs, and describe the challenges for their clinical use in diabetes cell therapy. Furthermore, we discuss the potential use of patient-specific PSCs as an in vitro model, providing new insights into the pathophysiology of diabetes. © 2014 Springer Science+Business Media New York.
Authors & Co-Authors
Abdelalim, E. M.
Qatar, Doha
Qatar Biomedical Research Institute
Egypt, Ismailia
Faculty of Medicine
Bonnefond, Amélie
Qatar, Doha
Qatar Biomedical Research Institute
France, Lille
Institut Pasteur de Lille
France, Lille
Université de Lille
France, Lille
European Institute Genomic for Diabetes Egid
Bennaceur-Griscelli, Annelise L.
France, Villejuif
Modèles de Cellules Souches Malignes et Thérapeutiques
France, Le Kremlin-bicetre
Hopital de Bicetre
Froguel, Philippe
Qatar, Doha
Qatar Biomedical Research Institute
France, Lille
Institut Pasteur de Lille
France, Lille
Université de Lille
France, Lille
European Institute Genomic for Diabetes Egid
United Kingdom, London
Hammersmith Hospital
Statistics
Citations: 51
Authors: 4
Affiliations: 8
Identifiers
Doi:
10.1007/s12015-014-9503-6
ISSN:
15508943
e-ISSN:
15586804
Research Areas
Cancer
Health System And Policy
Noncommunicable Diseases
Study Design
Cohort Study